Скачать или смотреть Key insights into long-term data for monotherapy from a leading expert

Dr Sharyn Lewin discusses key data for LYNPARZA® (olaparib) from the SOLO-1 study, including post hoc long-term follow-up analyses of the primary endpoint and a key secondary endpoint.
Learn more: https://www.lynparzahcp.com/ovarian-c...

In this video, Dr Sharyn Lewin, a leading gynecologic oncologist, discusses key data from the SOLO-1 study, including the post hoc 5-year PFS follow-up and prespecified 7-year OS analyses.

LYNPARZA is indicated as maintenance therapy for women with BRCAm* advanced ovarian cancer after response to first-line platinum-based chemotherapy.
*Select patients for this indication based on an FDA-approved companion diagnostic for LYNPARZA.

LYNPARZA is associated with serious and potentially fatal adverse events including myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), pneumonitis, venous thromboembolism (VTE) and drug-induced liver injury (DILI). Monitor patients for signs and symptoms and discontinue LYNPARZA if MDS/AML or pneumonitis is confirmed. Monitor patients for signs and symptoms of VTE and treat as medically appropriate. Evaluate bilirubin and transaminases at baseline and throughout treatment with LYNPARZA. If DILI is suspected, interrupt LYNPARZA. If DILI is confirmed, discontinue LYNPARZA. LYNPARZA can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception.

Please see complete Prescribing Information, including Medication Guide, at https://qr.short.az/LYNPARZAPI

You may report side effects related to AstraZeneca products by visiting: http://us-aereporting.astrazeneca.com